AIMM Therapeutics (Netherlands)
Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus™; on market and estimated to be a billion dollar plus product), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor
Basic Information
- Category: business
- Website: https://aimmtherapeutics.com
Documented Facts
- Phone: +31 (0) 20 566 21 45 (No linked source recorded for this statement.)
- Email: contact@klingbio.com (No linked source recorded for this statement.)
Evidence and Sources
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about AIMM Therapeutics (Netherlands).
- Canonical profile: https://brandsource.ai/brands/aimm-therapeutics-netherlands
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/aimm-therapeutics-netherlands/json-ld
- Citation profile API: https://brandsource.ai/api/brands/aimm-therapeutics-netherlands/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (80/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Kling-Select relies on a fully-owned and clinically-validated B cell immortalization technology to identify novel therapeutic targets and antibody binders from patients with exceptional clinical responses. This technology has successfully identified novel neutralizing antibodies for various infectious diseases such as RSV (nirsevimab/Beyfortus™; on market and estimated to be a billion dollar plus product), Covid, and Influenza. More recently, Kling-Select has been applied to peripheral and tumor
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.